Article Information
History
- July 22, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ziqi V Wang1,
- Badwi B Boumelhem1,
- Torsten Pennell1,
- William W Bachovchin2,
- Jack Hung-Sen Lai2,
- Sarah E Poplawski2,
- Pieter Van Der Veken3,
- Kate Brewer1,
- Geraldine Ooi4,
- Jacob George5,
- Mohamed Eslam5,
- Leon A Adams6,
- Hui Emma Zhang1,
- Geoffrey W McCaughan1,7,
- Avik Majumdar1,7,8,#,* and
- Mark D Gorrell1,*,#
- 1Liver Enzymes in Metabolism and Inflammation, Centenary Institute, and The Faculty of Medicine and Health, The University of Sydney, NSW, Australia
- 2Department of Developmental, Molecular and Chemical Biology, Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts, 02111, United States
- 3Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2610 Wilrijk, Belgium; Department of Surgery
- 4Monash University, Victoria, Australia
- 5Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, 2145
- 6Medical School, Faculty of Medicine and Health Sciences, The University of Western Australia, Australia
- 7AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW, 2050
- 8Department of Gastroenterology, Austin Hospital, Melbourne, Australia
- ↵#corresponding authors. mark.gorrell{at}sydney.edu.au; avik.majumdar{at}austin.org.au.
↵* Equal senior
Posted July 22, 2024.
Development and validation of a novel circulating fibroblast activation protein - based predictive model to improve fibrosis risk stratification in metabolic liver disease population
